- In March 2025, Thermo Fisher Scientific launched its next-generation GeneArt Gene Synthesis Service, featuring advanced error correction algorithms and increased throughput capabilities. This new platform aims to accelerate synthetic biology workflows by offering faster turnaround times and enhanced accuracy, catering to high-demand applications in therapeutics and vaccine development
- In January 2025, Twist Bioscience Corporation announced a strategic partnership with Ginkgo Bioworks to co-develop synthetic genes for engineered cell programs. The collaboration focuses on creating high-fidelity DNA sequences for use in bioindustrial manufacturing and pharmaceutical applications, leveraging Twist’s silicon-based DNA synthesis technology
- In November 2024, Codex DNA (now Telesis Bio) introduced the BioXp Select DNA Assembly Kit, a customizable gene synthesis solution designed for rapid, automated construction of synthetic genes and genetic circuits. This development supports researchers in synthetic biology and drug discovery by enabling same-day synthesis and cloning
- In October 2024, GenScript launched its CRISPR-optimized Gene Synthesis Platform, designed to provide high-quality, CRISPR-compatible DNA fragments for genome editing applications. The platform minimizes off-target effects and enhances editing efficiency, offering significant value for gene therapy and functional genomics research
- In August 2024, Integrated DNA Technologies (IDT) announced the expansion of its Ultramer DNA Oligos product line, now supporting longer and more complex gene constructs for advanced molecular biology applications. This development is aimed at researchers requiring ultra-pure, long synthetic DNA for genome assembly, synthetic biology, and personalized medicine
